Labetalol Hepatotoxicity
Authors: Eric L. Michelson
Journal: Annals of Internal Medicine (1991)

Letters15 February 1991Labetalol HepatotoxicityEric L. Michelson, MDEric L. Michelson, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-4-341 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: The article by Clark and colleagues (1) on labetalol-induced hepatocellular toxicity highlights the importance of postmarketing surveillance of drugs after they receive approval from the Food and Drug Administration (FDA). Relatively infrequent but serious adverse effects not uncommonly are either missed altogether or attributed erroneously to other causes. Moreover, even extensive use of a drug outside the United States before the FDA approves it cannot necessarily be accepted as fully informative. For example, a toxicity may be rare or study populations may be too highly selected.Labetalol's potential for hepatotoxicity was identified in the United States during...References1. ClarkZimmermanTanner JHL. Labetalol hepatotoxicity. Ann Intern Med. 1990;113:210-3. LinkGoogle Scholar2. MichelsonFrishmanLewis EWJ. Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension. Am J Med. 1983;75(Suppl 4A):68-80. CrossrefMedlineGoogle Scholar3. MichelsonFrishman EW. Labetalol: an alpha- and beta-adrenoceptor blocking drug. Ann Intern Med. 1983;99:553-5. LinkGoogle Scholar4. Special Report to the British Committee on Safety of Medicines. Incidence of Side Effects Associated with Labetalol. British Monitored Release Trials of 6,638 Patients. British Committee on Safety of Medicines; 1978. Google Scholar1. ClarkZimmermanTanner JHL. Labetalol hepatotoxicity. Ann Intern Med. 1990;113:210-3. LinkGoogle Scholar2. WallinFrishman JW. Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity. J Clin Pharmacol. 1989;29:1057-68. CrossrefMedlineGoogle Scholar3. ChrispGoa PK. Dilevalol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension. Drugs. 1990;39:234-63. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Eric L. Michelson, MDAffiliations: Hahnemann University Philadelphia, PA 19102 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBasil Oil is a Promising Skin Penetration Enhancer for Transdermal Delivery of Labetolol HydrochlorideCardiovascular Drug Therapy in Patients with Hepatic Diseases and Patients with Congestive Heart FailureHEPATOTOXICITY OF ANTICHOLESTEROL, CARDIOVASCULAR, AND ENDOCRINE DRUGS AND HORMONAL AGENTSDrug-Induced HepatotoxicityConjonctivite et œdème des paupières par allergie de contact à quatre bêta-bloquants utilisés en collyresDrug-induced hepatotoxicityAspects actuels des risques des médicaments anti-hypertenseurs en immuno-allergologieHypersensitivity Immune Reaction as a Mechanism for Dilevalol-Associated HepatitisDrug Information Analysis Serviceβ-adrenoceptor antagonists and antianginal drugsβ-adrenoceptor antagonists and antianginal drugs 15 February 1991Volume 114, Issue 4Page: 341-341KeywordsAdverse reactionsDrug administrationDrugsFood and Drug AdministrationPopulation statisticsToxicity ePublished: 1 December 2008 Issue Published: 15 February 1991 PDF downloadLoading ...